Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background As the coronavirus disease 2019 (COVID-19) vaccination campaign unfolds, it is important to continuously assess the real-world safety of Food and Drug Administration (FDA)-authorized vaccines. Curation of large-scale electronic health records (EHRs) enables near-real-time safety evaluations that were not previously possible. Methods In this retrospective study, we deployed deep neural networks over a large EHR system to automatically curate the adverse effects mentioned by physicians in over 1.2 million clinical notes between December 1, 2020 and April 20, 2021. We compared notes from 68,266 individuals who received at least one dose of BNT162b2 (n = 51,795) or mRNA-1273 (n = 16,471) to notes from 68,266 unvaccinated individuals who were matched by demographic, geographic, and clinical features. Findings Individuals vaccinated with BNT162b2 or mRNA-1273 had a higher rate of return to the clinic, but not the emergency department, after both doses compared to unvaccinated controls. The most frequently documented adverse effects within 7 days of each vaccine dose included myalgia, headache, and fatigue, but the rates of EHR documentation for each side effect were remarkably low compared to those derived from active solicitation during clinical trials. Severe events, including anaphylaxis, facial paralysis, and cerebral venous sinus thrombosis, were rare and occurred at similar frequencies in vaccinated and unvaccinated individuals. Conclusions This analysis of vaccine-related adverse effects from over 1.2 million EHR notes of more than 130,000 individuals reaffirms the safety and tolerability of the FDA-authorized mRNA COVID-19 vaccines in practice. Funding This study was funded by nference.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding
Devlin, J., Chang, M.-W., Lee, K., & Toutanova, K. (2019) · Proceedings of the 2019 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies, Volume 1 (Long and Short Papers) · doi:10.18653/v1/n19-1423 · Cited by 54,325
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Shimabukuro, T. T., Cole, M., & Su, J. R. (2021) · JAMA · doi:10.1001/jama.2021.1967 · Cited by 475
Maintaining safety with SARS-CoV-2 vaccines
Castells, M. C., & Phillips, E. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2035343 · Cited by 395 · cited 1×
“Notably, these rates of adverse effects documented in EHR notes were markedly lower than the rates of adverse effects observed in clinical trials (e.g., fatigue [63%–70%], myalgia [38%–62%], arthralgia [24%–46%], fever [14%–16%], and ery-thema [10%–15”
Bell's palsy and SARS-CoV-2 vaccines
Ozonoff, A., Nanishi, E., & Levy, O. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00076-1 · Cited by 158
Cited by
Liu, Q., Qin, C., Liu, M., & Liu, J. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00915-3 · Cited by 341
Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-Garcia, J., O’Horo, J. C., Virk, A., Swift, M. D., Halamka, J., Badley, A. D., et al. (2021) · medRxiv · doi:10.1101/2021.08.06.21261707 · Cited by 255
Self-citationMoving towards vertically integrated artificial intelligence development
Zhang, J., Budhdeo, S., William, W., Cerrato, P., Shuaib, H., Sood, H., Ashrafian, H., Halamka, J., & Teo, J. T. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00690-x · Cited by 54
Self-citationRafati, A., Pasebani, Y., Jameie, M., Yang, Y., Jameie, M., Ilkhani, S., Amanollahi, M., Sakhaei, D., Rahimlou, M., & Kheradmand, A. (2023) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2023.0160 · Cited by 45
Walker, J. L., Schultze, A., Tazare, J., Tamborska, A., Singh, B., Donegan, K., Stowe, J., Morton, C. E., Hulme, W. J., Curtis, H. J., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.010 · Cited by 30
Metadata
- Authors
- McMurry, R., Lenehan, P., Awasthi, S., Silvert, E., Puranik, A., Pawlowski, C., Venkatakrishnan, A. J., Anand, P., Agarwal, V., O’Horo, J. C., Gores, G. J., Williams, A. W., Badley, A. D., Halamka, J., Virk, A., Swift, M. D., Carlson, K., Doddahonnaiah, D., Metzger, A., Kayal, N., Berner, G., Ramudu, E., Carpenter, C., Wagner, T., Rajasekharan, A., & Soundararajan, V.
- Venue
- Med
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 2
- Issue
- 8
- Pages
- 965-978.e5
- ISSN
- 2666-6340 (ISSN-L)
- OpenAlex
- W3177052412
- Cited by
- 67
- References
- 8
- FWCI
- 32.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. https://app.cochat.ai/papers/10.1016/j.medj.2021.06.006
- The paper
- McMurry, R., Lenehan, P., Awasthi, S., Silvert, E., Puranik, A., Pawlowski, C., Venkatakrishnan, A. J., Anand, P., Agarwal, V., O’Horo, J. C., Gores, G. J., Williams, A. W., Badley, A. D., Halamka, J., Virk, A., Swift, M. D., Carlson, K., Doddahonnaiah, D., Metzger, A., . . . Soundararajan, V. (2021). Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med. https://doi.org/10.1016/j.medj.2021.06.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.